2 Diabetes Medications Carry Risks for Kidney Patients, FDA Says

Drugs containing saxagliptin or alogliptin may be linked to heart failure risk.
Drugs containing saxagliptin or alogliptin may be linked to heart failure risk.

(HealthDay News) -- Diabetes medications containing saxagliptin and alogliptin may raise the risk of heart failure, particularly in patients with heart or kidney disease, US health officials warned Tuesday.

The FDA said its warning was based on results of 2 large trials done involving patients with heart disease. Both trials found that more patients taking drugs containing saxagliptin or alogliptin were hospitalized for heart failure than patients receiving a placebo.

In the saxagliptin trial, 3.5% of patients receiving the drug were hospitalized for heart failure, compared with 2.8% of patients receiving a placebo. Risk factors included a history of heart failure or kidney impairment, the FDA reported. In the alogliptin trial, 3.9% of patients taking the drug were hospitalized for heart failure, compared with 3.3% receiving a placebo.

The FDA said it's asking doctors to consider discontinuing medications containing saxagliptin and alogliptin in patients who develop heart failure. If blood glucose is not well-controlled with current treatments, other diabetes drugs may be needed, the agency said.

Source

  1. Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication - Risk of Heart Failure [news release]. FDA. April 5, 2016.
Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup